Guggenheim initiated coverage of Illumina with a Buy rating and $155 price target. The analyst initiated coverage on nine select specialty tools and specialty diagnostic lab companies. The life sciences tools group remains a large and growing industry where innovation expands applications and opens up new markets, the analyst tells investors in a research note. The firm says that over time, these applications can enable the development of disruptive therapies. Guggenheim’s top picks are Illumina (ILMN), Natera (NTRA) and Exact Sciences (EXAS).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ILMN:
- Illumina initiated with bullish view at Wolfe Research, here’s why
- Illumina initiated with bullish view at Wolfe Research
- Zillow upgraded, Airbnb downgraded: Wall Street’s top analyst calls
- Illumina just downgraded at BofA, here’s why
- Illumina submits Form 10 to SEC related to potential GRAIL divestiture